Cardiovascular Disease and CAD
Cardiovascular diseases (CVDs), including heart disease and stroke, are the most significant causes of death, accounting for more than one-third of all US deaths. In 2010, the total cost of treating CVDs in the US alone was estimated to be $444 billion. Coronary Artery Disease (CAD) accounts for 75% of CVD deaths and is caused by rupture of an atheromatous plaque.
New therapies that successfully treat CAD could make a dramatic difference to the welfare of patients. However, effective and targeted treatments for CAD have evaded the traditional pharmacological and medical device approaches, despite the increase in resolution of analytical technologies and imaging systems.
PlaqueTec has developed a revolutionary new proprietary platform that is uniquely positioned to transform the understanding of CAD and provide the information from which new therapies can be developed.
First, there are individuals who remain at high risk for cardiovascular events but are not identified by the factors included in calculations of risk.
Second, such biomarkers are critical to drug development decision-making, particularly for drugs that work through a mechanism of action that does not alter LDL cholesterol…
Third, the application of these markers is relevant to assessing atherosclerosis risk in the development of drugs for other indications.”
From: ‘Atherosclerosis drug development in jeopardy: the need for predictive biomarkers of treatment response’ Sci Transl Med, 2011. 3(72))
Given the high cost and risk of atherosclerosis drug development programs, without these markers there has been a decreased investment in the therapeutic area and an exodus of pharmaceutical companies from atherosclerosis as a targeted indication. As CVD remains the dominant cause of mortality globally and high residual cardiovascular risk remains even after LDL-cholesterol is reduced, society will bear the burden of the lack of new drugs.